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Genetic Risk of Diverticular Disease Predicts 
Early Stoppage of Nicorandil
James D. Noyes1, Ify R. Mordi1, Alexander S. Doney2, Colin N. A. Palmer2, Ewan R. Pearson2 and  
Chim C. Lang1,*
Gastrointestinal fistulation has been widely reported as an adverse effect of nicorandil therapy in Europe. People 
who have underlying diverticular disease are most at risk of this side effect. In Western countries, diverticular 
disease is highly prevalent and can be clinically silent. This study aimed to identify diverticular disease genetic risk 
scores (GRSs) associated with early nicorandil stoppage, a surrogate marker for drug intolerance. A case-control 
study was carried out on 1,077 patients from the Genetics of Diabetes Audit and Research Tayside Scotland 
(GoDARTS) database. Cases were defined as having < 9 nicorandil prescriptions with no identifiable reason for 
stopping (n = 230). Controls had either ≥ 9 prescriptions, treatment continuation to death/study end or stoppage 
post-myocardial infarction. Two diverticular GRSs were created and used in logistic regression models. Isosorbide 
mononitrate was used as a control analysis. Patients with a raised diverticular GRS, based on 23 replicable loci, had 
increased risk of stopping nicorandil therapy early (univariate (odds ratio (OR) 2.26; P = 0.04], multivariate (OR 3.96; 
P = 0.01)). Similar trends were noted when using the full 42 variant diverticular score but statistical significance was 
not reached. The isosorbide control analysis did not reach statistical significance. Our analysis demonstrates a novel 
positive association between a raised diverticular GRS and early stoppage of nicorandil therapy.
Nicorandil is an anti-anginal agent recommended by European 
Society of Cardiology guidelines1 as second-line therapy after 
beta blockers, calcium channel blockers, and long-acting ni-
trates. There is, however, increased recognition of side effects 
associated with nicorandil, in particular skin, mucosal, and 
gastrointestinal ulcers, which may progress to perforation, hem-
orrhage, fistula, or abscess.2 Individuals with diverticular dis-
ease are seven times more likely to develop a fistula when taking 
nicorandil.3 However, many patients with diverticular disease 
are asymptomatic, therefore, identification of patients at high-
risk for developing gastrointestinal side effects with nicorandil 
use is difficult.
One potential approach to predict the risk of an off-target ad-
verse drug effect is to study the patient’s genetic profile. In support 
of this approach is identification of the SLCO1B1 variant that is 
associated with statin intolerance4 and the rs3788853 variant of 
XPNPEP2 that may be associated with angiotensin-converting 
enzyme inhibitor-related angioedema.5 Recent genomewide as-
sociation studies have identified genetic variants associated with 
diverticular disease.6 We hypothesized that patients at increased 
genetic risk of diverticular disease are more likely to develop ad-
verse drug effects from nicorandil requiring treatment cessation. 
This study aimed to identify genetic risk scores (GRSs) associ-
ated with early nicorandil stoppage, a surrogate marker for drug 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Patients with diverticular disease are seven times more likely 
to develop a fistula when taking nicorandil. In the Western 
world, ~ 50% of those aged over 60 years are predicted to have 
diverticular disease although many will have no symptoms, 
hence it would be beneficial to have a method of identifying peo-
ple at higher risk for diverticular disease without colonoscopy.
WHAT QUESTION DID THIS STUDY ADDRESS?
 To establish whether the use of diverticular disease genetic 
risk scores (GRSs) could predict nicorandil intolerance, meas-
ured by early nicorandil stoppage.
WHAT DOES THIS STUDY ADD TO OUR KNOW- 
LEDGE?
 This study shows that a raised diverticular disease GRS is 
associated with early nicorandil stoppage.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 Formal screening, for example, using colonoscopy, for di-
verticular disease is not currently undertaken prior to the 
initiation of nicorandil therapy. Our findings could provide 
clinicians with a means to prospectively identify those most at 
risk of nicorandil’s adverse effects, allowing an alternative anti-
anginal therapy to be offered.
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intolerance. As a control, we have also evaluated the effect of these 
same GRSs on stoppage of isosorbide mononitrate.
METHODS
Study cohort
The cohort for this analysis is the Genetics of Diabetes Audit and 
Research in Tayside Scotland (GoDARTS) database, details of which 
have been previously published.7 In summary, the GoDARTS study re-
cruited a population of 10,149 individuals with type 2 diabetes (T2D) 
and 8,157 controls without T2D. At recruitment, participants consented 
to access of their retrospective and prospective prescribing, biochemi-
cal, and baseline data for research purposes. This generated a compre-
hensive longitudinal electronic medical record for patients with T2D in 
the Tayside area with matched controls. Ethical approval was granted to 
the GoDARTS study by the Tayside Committee on Medical Research 
Ethics (REC reference 053/04) and the GoDARTS Access Committee 
approved our proposal (Ref GD0075).
Genotyping
Blood samples were obtained from patients who previously consented 
for DNA extraction and these samples were linked to their electronic 
medical records, as previously described. Genotyping was carried out 
across five platforms: Affymetrix Genome-Wide Human SNP Array 6.0, 
Illumina HumanOmni Express, SHAPEIT14, IMPUTE2, and various 
custom genotyping arrays from Illumina.7
Derivation of GRSs
A recent publication using UK Biobank data revealed 48 genetic variants 
that were associated with diverticular disease. Of these, 27 variants were 
replicated in a second European cohort.6 In our analysis, two divertic-
ular weighted GRSs were created: the first with replicable variants and 
the second with all diverticular associated variants included. Genetic 
data were available for 23 and 42 loci, respectively, from GoDARTS. To 
calculate the patient’s weighted GRS, the natural log of the published 
odds ratio (OR) was determined for each effect variant contributing to 
the GRS. The sum of these values formed the patient’s weighted GRS. 
The mean variant value for the cohort was used for missing variant data. 
Numbers of missing variants and the variants included in each score are 
shown in Table S1.
Outcomes
A pharmaco-epidemiological study, which used the GoDARTS data-
base, was performed to examine associations between select GRSs and 
nicorandil intolerance, measured by early drug stoppage. The selection 
process to determine the cases and controls is described in Figure 1. 
The control group included patients who had their final nicorandil pre-
scription in the 6  months preceding their death or the end of study 
data collection date. These patients were assumed not to have stopped 
nicorandil therapy due to intolerance. Additionally, patients who had 
their final nicorandil prescription in the 6 months before a myocardial 
infarction were assumed to have undergone revascularization therapy, no 
longer requiring an anti-anginal drug. These patients were added to the 
control group too, as they did not stop nicorandil due to adverse effects. 
The remaining patients were further stratified based on their number of 
nicorandil prescriptions to identify a case group who stopped nicorandil 
early. The median quantity of tablets per prescription was 84, and the 
most frequently prescribed dose was one tablet, twice a day. Nine pre-
scriptions equate to roughly 1 year of treatment and any patient with nine 
or more prescriptions of nicorandil was added to the control group; the 
remaining patients were the cases (n = 230). Two patients were removed 
due to their final prescription being > 1 month after their death and one 
patient was removed due to missing baseline data.
As a further analysis, we also determined the association between the 
genetic risk scores and early stoppage of isosorbide mononitrate (ISMN). 
ISMN is another anti-anginal, which is rarely used for any other indica-
tions (similar to nicorandil), but has not been associated with gastrointesti-
nal ulceration or diverticular disease, therefore, we would not expect there 
to be an association between the GRS and ISMN stoppage. GoDARTS 
data contained 3,003 patients who were prescribed ISMN. The nicorandil 
Figure 1 Selection process to determine the cases and controls.
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and IMSN datasets were not exclusive and 911 patients were prescribed 
both drugs. The previously described methods were applied in the same 
way to this cohort. Six patients in this analysis were removed as their final 
prescription was > 1 month after their death and one patient was removed 
due to missing baseline data. In total, 2,996 patients who met the inclu-
sion criteria were identified in the database, 801 cases and 2,195 controls 
(Figure 1).
Drug dose for both nicorandil and ISMN was categorized into four 
groups: low, medium, high, and unknown dose. The categories were cre-
ated based on the spread of prescribing instructions available from the 
GoDARTS database. The total dose of two tablets a day was used as a me-
dium dose for both cohorts. Any dose above or below this was classified 
as low or high, respectively. In both cohorts, any prescribing instruction 
that was not clear was classified as unknown. Tablet strength data was not 
available from GoDARTS.
Statistical analysis
The mean and SD were calculated for continuous covariates, and frequen-
cies of each group were determined for categorical covariates (Table 1). 
Initial univariate logistic regression analyses were carried out among our 
dependent variable, early nicorandil stoppage, and the two weighted 
GRSs. Multivariate logistic models were subsequently generated with the 
following covariates: weighted GRS, age, sex, drug dose, and number of 
days between the first and last prescription. The multivariate analysis was 
repeated for each weighted GRS. The same process was carried out for 
our control ISMN cohort. Statistical analyses were conducted using R 
version 3.6.1 with statistical significance set at P < 0.05.
RESULTS
Baseline data are presented for both the nicorandil and ISMN 
analysis in Table 1. Univariate logistic regression models were 
used to test for associations between early nicorandil stoppage 
and each GRS independently. A positive univariate association 
was identified between the diverticular GRS comprised of 23 
replicable loci and early stoppage of nicorandil (OR 2.26, 95% 
confidence interval (CI) 1.02–4.99, P = 0.04). The multivariate 
model adjusted for sex, age, number of days between first and last 
prescription, and drug dose showed an even stronger association 
(OR 3.96, 95% CI 1.35–12.17, P = 0.01).
The diverticular GRS comprised of all available 42 loci was also 
tested in a univariate model revealing again a positive association 
with early stoppage of nicorandil, but the association was weaker 
than the 23 variant model and did not reach statistical significance 
(OR 1.45, 95% CI 0.77–2.74, P = 0.25). The multivariate model 
increased the odds of early stoppage compared with the univariate 
model but did not reach statistical significance (OR 2.14, 95% CI 
0.93–5.01, P = 0.07).
The same models were applied to the ISMN cohort that showed 
weaker associations in both scores, which were not statistically 
significant. The results for the univariate ISMN analyses are: 23 
diverticular loci (OR 1.49, 95% CI 0.92–2.40, P = 0.1) and full 42 
diverticular loci (OR 1.29, 95% CI 0.88–1.88, P = 0.19). The mul-
tivariate analyses results are: 23 diverticular loci (OR 1.99, 95% CI 
0.95–4.17, P = 0.07) and full 42 diverticular loci (OR 1.19, 95% 
CI 0.67–2.13, P = 0.55).
DISCUSSION
The results of this analysis show, we believe for the first time, that 
increased genetic risk of diverticular disease predicts early stop-
page of nicorandil treatment but not ISMN.
Nicorandil was first prescribed in Japan in 1984. In 1997, the 
first reports appeared of gastrointestinal ulceration and fistulation 
in association with nicorandil use.3,8,9 General consensus from 
these initial case reports and observational studies was that the ad-
verse effects cannot be predicted. However, more recent data have 
shown that individuals with diverticular disease are at an increased 
risk of bowel perforation10 and are seven times more likely to de-
velop a fistula.3 These observational data support our analysis that 
Table 1 Baseline characteristics of nicorandil and isosorbide mononitrate cohorts
Characteristic














Female 429 (39.8) 330 (39.0) 99 (43.0) 1,248 (41.7) 903 (41.1) 345 (43.1)
Male 648 (60.2) 517 (61.0) 131 (57.0) 1,748 (58.3) 1,292 (58.9) 456 (56.9)
Age, years 68.0 (10.5) 67.7 (10.4) 68.8 (10.7 64.7 (11.1) 65.3 (10.9) 63.3 (11.4)
Dose, n (%)
Low 98 (9.1) 68 (8.0) 30 (13.0) 1,091 (36.4) 699 (31.8) 392 (48.9)
Medium 654 (60.7) 480 (56.7) 174 (75.7) 961 (32.1) 638 (29.1) 323 (40.3)
High 22 (2.0) 14 (1.7) 8 (3.5) 53 (1.8) 23 (1.0) 30 (3.7)
Unknown 303 (28.1) 285 (33.6) 18 (7.8) 891 (29.7) 835 (38.0) 56 (7.0)














Diabetes diagnosis, n (%) 817 (75.9) 659 (77.8) 158 (68.7) 2,137 (71.3) 1,628 (74.2) 509 (63.5)
23 variant diverticular GRS −0.07 (0.18) −0.07 (0.17) −0.05 (0.19) −0.07 (0.17) −0.07 (0.17) −0.06 (0.15)
42 variant diverticular GRS 0.14 (0.23) 0.14 (0.23) 0.16 (0.23) 0.14 (0.21) 0.14 (0.22) 0.15 (0.20)
Values are reported as the mean (SD), unless indicated otherwise.
GRS, genetic risk score.
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an individual’s genetic risk might be useful in identifying patients 
at high-risk of nicorandil-induced gastrointestinal side effects.
Scandinavian twin studies have shown that diverticular disease has 
a significant heritable component of up to 50%.11–13 Epidemiological 
studies have estimated that 50% of those aged over 60 years old in the 
Western world have diverticular disease compared with a prevalence 
of < 0.5% in Asia.14 This finding does not seem to be influenced by 
changes in environmental factors, demonstrated by migrant studies, 
suggesting that the difference in prevalence is mediated through a 
genetic mechanism.15–17 The genomewide association studies show-
ing associations to diverticular disease were completed in European 
cohorts and are likely to be specific to white patients. The genetic 
variance between populations may explain why there were no pub-
lished reports of gastrointestinal adverse events associated with 
nicorandil use during the 10-year post-approval period in Japan. In 
France, nicorandil was approved for use in 1994 and the first report of 
nicorandil-induced mouth ulcerations was published 3 years later.18
Diverticula most often occur at vulnerable sites where blood 
vessels cross the colon muscle wall. It is hypothesized that in these 
outpouchings, nicorandil’s toxic metabolites accumulate caus-
ing epithelial proliferation and subsequent tissue ulceration.8 
Additionally, it has been postulated that nicorandil releases proin-
flammatory nitric oxide, which may also trigger the development 
of fistulas among sigmoidal diverticula.3
The main clinical implication of our study is the potential for 
the use of a GRS to predict adverse side effects with nicorandil 
use. Genotyping can now be undertaken for £30/$40 allowing for 
the future development of a clinical decision support tool to guide 
prescribing.19 If patients were found to have an elevated weighted 
GRS based on our 23 variant score, shown in Table S1, we pro-
pose that an alternative anti-anginal is prescribed. Importantly, this 
weighted GRS was not associated with early stopping of ISMN.
There are potential limitations to our study, mainly contributed 
to the challenges of using retrospective prescribing data. Only 19 
patients in the nicorandil group had International Classification 
of Diseases codes for any form of ulceration or fistula, seven of 
which continued their treatment until death, end of study date, 
or stopped due to myocardial infarction. Additionally, the use 
of GoDARTS data does not permit review of individual patient 
notes. Therefore, information regarding drug dosing and exact du-
ration of treatment was inaccessible. Assumptions also had to be 
made based on the general prescribing prediction that nicorandil 
is rarely stopped once started. In addition, as highlighted in Table 
S1, not all variants had been genotyped for every patient and the 
mean variant value had to be substituted in a number of instances. 
Despite these obstacles we have identified a GRS that is strongly 
associated with stoppage of nicorandil, providing for the first time 
a predictive tool to reduce the risk of adverse effects.
CONCLUSION
Our analysis has identified that use of a GRS for increased like-
lihood of diverticular disease was associated with early stoppage 
of nicorandil treatment. This highlights the potential for use of a 
pharmacogenomic strategy in prescribing nicorandil, which could 
be an additional tool to help clinicians identify the optimal pre-
scribing choice for each individual patient.
SUPPORTING INFORMATION
Supplementary information accompanies this paper on the Clinical 
Pharmacology & Therapeutics website (www.cpt-journal.com).
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